Using Contact Lenses and Spectacle Lenses as Myopia Interventions.

• Test Spectacle Lens & Contact Lens (Device): Participants will wear contact lenses for a target of 10 hours a day, 5 days per week and test spectacle lenses for remaining waking hours.
• Control Spectacle Lens & Contact Lens (Device): Participants will wear contact lenses for a target of 10 hours a day, 5 days per week and control spectacle lenses for remaining waking hours.

Primary outcomes

• Change in axial length (AXL, mm) over 12 months [Over 12 months]

Sex: All, ages: 11 Years to 17 Years

Inclusion Criteria:

* Are aged 11 to 17 years (inclusive);
* Have successfully completed the 4-year MiSight® Analysis of Progression (MAP) Study;
* Are established soft contact lens wearers (including myopia control contact lens designs);
* Have read and signed the study consent or assent form, as appropriate for their age;
* Have a parent or legal guardian who has read and signed the Parent/Guardian Information Sheet (PIS) and Consent Form;
* Are willing and able to follow study instructions and maintain the appointment schedule;
* Are willing to wear the study contact lenses for 10 hours/day and 5 days per week as an ideal target while participating;
* Require a spherical contact lens power correction between -0.50 and -6.00 D;
* Have astigmatism not exceeding 2.00 DC in each eye by subjective refraction;
* Have best-corrected visual acuity of 0.10 logMAR (approx. 20/25 Snellen) or better in each eye;
* Have ocular health findings (biomicroscopy) that do not contraindicate contact lens wear;
* Continue to demonstrate acceptable fit and handling with the study contact lenses.

Exclusion Criteria:

* Are participating in any concurrent clinical or interventional study;
* Have worn rigid gas-permeable (including orthokeratology) contact lenses within the previous 30 days;
* Have used atropine concentrations above 0.01% for myopia control in the previous 30 days;
* Are extended-wear contact lens users (i.e., sleep in their lenses);
* Have best-corrected visual acuity worse than 0.10 logMAR in either eye;
* Have any current or evolving ocular or systemic condition that could affect visual function, ocular growth, or contact lens wear;
* Have any clinically significant corneal or conjunctival staining with sodium fluorescein, or other ocular findings contraindicating contact lens wear;
* Are using systemic or topical medications known or expected to affect pupil size, tear production, accommodation, refractive state, or any study outcome variable;
* Have a history of ocular surgery, keratoconus, or other forms of irregular cornea, or are aphakic;
* Have diagnosed accommodative and/or binocular vision anomalies, including amblyopia, strabismus, or nystagmus;
* Have known sensitivity or allergy to any of the diagnostic agents used in the study;
* Have any systemic condition that, in the opinion of the investigator, may influence study outcomes or contraindicate soft contact lens wear, including pregnancy;
* Are a child of an employee of either clinical site directly involved in the study.

• Baskar Arumugam, PhD, Study chair, CooperVision, Inc.
• Debbbie Laughton, Study chair, SightGlass Vision, Inc.